LLY

784.56

-0.86%↓

JNJ

150.85

-0.97%↓

NVO

74.09

-0.39%↓

ABBV

185.38

+0.09%↑

UNH

307.09

-0.49%↓

LLY

784.56

-0.86%↓

JNJ

150.85

-0.97%↓

NVO

74.09

-0.39%↓

ABBV

185.38

+0.09%↑

UNH

307.09

-0.49%↓

LLY

784.56

-0.86%↓

JNJ

150.85

-0.97%↓

NVO

74.09

-0.39%↓

ABBV

185.38

+0.09%↑

UNH

307.09

-0.49%↓

LLY

784.56

-0.86%↓

JNJ

150.85

-0.97%↓

NVO

74.09

-0.39%↓

ABBV

185.38

+0.09%↑

UNH

307.09

-0.49%↓

LLY

784.56

-0.86%↓

JNJ

150.85

-0.97%↓

NVO

74.09

-0.39%↓

ABBV

185.38

+0.09%↑

UNH

307.09

-0.49%↓

Search

Actinium Pharmaceuticals Inc

Abierto

1.45 2.11

Resumen

Variación precio

24h

Actual

Mínimo

1.4

Máximo

1.46

Métricas clave

By Trading Economics

Ingresos

-9.3M

-16M

BPA

-0.51

Empleados

31

EBITDA

-9.3M

-17M

Recomendaciones

By TipRanks

Recomendaciones

Compra Fuerte

Estimación a 12 meses

+319.58% upside

Dividendos

By Dow Jones

Próximas Ganancias

1 ago 2025

Estadísticas de Mercado

By TradingEconomics

Capitalización de Mercado

-624K

48M

Apertura anterior

-0.66

Cierre anterior

1.45

Actinium Pharmaceuticals Inc Gráfico

El rendimiento pasado no es un indicador fiable de resultados futuros.

Noticias Relacionadas

18 jun 2025, 17:32 UTC

Principales Movimientos del Mercado

Lion Group Shares Climb on $600 Million Loan for Crypto Treasury

18 jun 2025, 23:55 UTC

Adquisiciones, fusiones, absorciones

Nippon Steel: To Book Restructuring Loss Related to This Sale in 1Q

18 jun 2025, 23:53 UTC

Adquisiciones, fusiones, absorciones

Nippon Steel: NS Kote Is an Entity That Owns All of Company's Equity Stake in AM/NS Calvert

18 jun 2025, 23:50 UTC

Adquisiciones, fusiones, absorciones

Nippon Steel: To Book About Y230B Loss Related to Sale of NS Kote to ArcelorMittal

18 jun 2025, 23:50 UTC

Charlas de Mercado

Australian Uranium Stocks Tipped to Go Higher -- Market Talk

18 jun 2025, 23:43 UTC

Charlas de Mercado

Gold Edges Higher Amid Ongoing Geopolitical Tensions -- Market Talk

18 jun 2025, 23:43 UTC

Charlas de Mercado

Global Equities Roundup: Market Talk

18 jun 2025, 23:43 UTC

Charlas de Mercado

Nikkei May Decline Amid Middle East Uncertainty -- Market Talk

18 jun 2025, 23:07 UTC

Charlas de Mercado

Fletcher Building Recovery May Be More Muted Than Thought -- Market Talk

18 jun 2025, 23:00 UTC

Charlas de Mercado

Smart Glasses Seen as Possible Future Agentic AI Platform -- Market Talk

18 jun 2025, 21:50 UTC

Charlas de Mercado

Argentina Poised To Become Significant LNG Exporter, Rystad Says -- Market Talk

18 jun 2025, 20:50 UTC

Charlas de Mercado

Tech, Media & Telecom Roundup: Market Talk

18 jun 2025, 20:38 UTC

Adquisiciones, fusiones, absorciones

U.S. Steel and Nippon Finalize Their 'Partnership.' What Comes After the Merger. -- Barrons.com

18 jun 2025, 20:32 UTC

Ganancias

These Stocks Moved the Most Today: Tesla, Marvell, Sunrun, Nucor, Circle Internet, Korn Ferry, GMS, and More -- Barrons.com

18 jun 2025, 19:59 UTC

Charlas de Mercado

Oil Edges Up as Next Steps in Iran Conflict Eyed -- Market Talk

18 jun 2025, 19:42 UTC

Charlas de Mercado

Natural Gas Extends Gains for Fourth Session -- Market Talk

18 jun 2025, 19:40 UTC

Ganancias

Fed Holds Rates Steady and Keeps Door Open to Cuts -- 3rd Update

18 jun 2025, 18:47 UTC

Adquisiciones, fusiones, absorciones

Railroads Have Slashed Costs and Raised Prices. Why One CEO Now Favors a Merger. -- Barrons.com

18 jun 2025, 18:33 UTC

Charlas de Mercado

Fitch Says U.S. Fiscal Outlook Remains Challenging -- Market Talk

18 jun 2025, 18:26 UTC

Charlas de Mercado

Market Talk Roundup: Latest on U.S. Politics

18 jun 2025, 18:26 UTC

Charlas de Mercado

Nucor, Steel Dynamics Seen Diverging In Approach To Current Business Climate -- Market Talk

18 jun 2025, 18:15 UTC

Charlas de Mercado

Gold Stays Flat After Fed Decision -- Market Talk

18 jun 2025, 17:42 UTC

Adquisiciones, fusiones, absorciones

ArcelorMittal Expects Related 2Q Gain of About $1.5B

18 jun 2025, 17:40 UTC

Adquisiciones, fusiones, absorciones

ArcelorMittal Completes Acquisition of Nippon Steel's 50% Interest in AM/NS Calvert

18 jun 2025, 17:20 UTC

Ganancias

Credit Card Annual Fees Are Going Up. What It Means for the Stocks. -- Barrons.com

18 jun 2025, 16:52 UTC

Charlas de Mercado

Trump Awakens Canada On Need For Fewer Trade Barriers, Macklem Says -- Market Talk

18 jun 2025, 16:31 UTC

Adquisiciones, fusiones, absorciones

Nippon Steel Completes Purchase of U.S. Steel After Reaching Security Deal With Trump Administration -- Update

18 jun 2025, 16:20 UTC

Charlas de Mercado

Basic Materials Roundup: Market Talk

18 jun 2025, 16:20 UTC

Charlas de Mercado

Auto & Transport Roundup: Market Talk

18 jun 2025, 16:20 UTC

Charlas de Mercado

Tech, Media & Telecom Roundup: Market Talk

Comparación entre iguales

Cambio de precio

Actinium Pharmaceuticals Inc Esperado

Precio Objetivo

By TipRanks

319.58% repunte

Estimación a 12 meses

Media 6 USD  319.58%

Máximo 9 USD

Mínimo 4 USD

De acuerdo con 3 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Actinium Pharmaceuticals Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

3 ratings

3

Comprar

0

Mantener

0

Vender

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Actinium Pharmaceuticals Inc

Actinium Pharmaceuticals, Inc. develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. Its Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with relapsed and refractory acute myeloid leukemia (r/r AML). The company focuses on advancing its development for product candidate Actimab-A, a therapeutic agent that has demonstrated potential activity in r/r AML patients. In addition, it engages with the National Cancer Institute under the cooperative research and development agreement for the development of Actimab-A in AML and other myeloid malignancies. Its Iomab-ACT, a next generation conditioning candidate, is being developed for improving patient access and outcomes for curative cell and gene therapies. Further, the company's research and development activities primarily focus on advancing various preclinical programs for solid tumor indications. The company holds approximately 235 patents and patent applications, including various patents related to the manufacture of the isotope Ac-225 in a cyclotron. The company is based in New York, New York.